Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 4:18 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 361–384 of 439 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Excretion Clear all
Completed Not applicable Interventional

Fosrenol and Phosphorus Balance - Lanthanum Carbonate

NCT01581996
View directory record Official record
Conditions
Chronic Kidney Failure, End-stage Renal Disease, Disorders Associated With Peritoneal Dialysis
Interventions
lanthanum carbonate
Drug
Lead sponsor
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Other
Eligibility
30 Years to 65 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Torrance, California
Source: ClinicalTrials.gov public record
Updated May 9, 2017 · Synced Oct 19, 2026, 4:18 PM EDT
Completed Not applicable Interventional

This Study Will Collect Clinical and Patient Reported Satisfaction Data From Males Requiring Urine Output Management Overnight in the Home Setting.

NCT06850259
View directory record Official record
Conditions
Urinary Incontinence
Interventions
PureWick™ System, UltraFlex™ Self-Adhering Male External Catheter
Device
Lead sponsor
C. R. Bard
Industry
Eligibility
65 Years and older · Male only
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
2
States / cities
Greenacres City, Florida • Hamilton, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 29, 2025 · Synced Oct 19, 2026, 4:18 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study To Investigate The Absorption, Distribution, Metabolism, And Excretion Of [14c]PF-06463922 In Healthy Male Volunteers

NCT02564562
View directory record Official record
Conditions
Healthy
Interventions
[14C] PF-06463922
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Dec 4, 2015 · Synced Oct 19, 2026, 4:18 PM EDT
Withdrawn No phase listed Observational Accepts healthy volunteers

A Multi-Center Protocol for Obtaining and Storing Human Samples for Immediate or Future Microbial, Immune, or Host Microbe Scientific Study

NCT00765141
View directory record Official record
Conditions
Infection
Interventions
Not listed
Lead sponsor
Southwest Regional Wound Care Center
Other
Eligibility
18 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Lubbock, Texas
Source: ClinicalTrials.gov public record
Updated Nov 26, 2015 · Synced Oct 19, 2026, 4:18 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Compare How the Body Absorbs, Distributes and Excretes the Drug Selitrectinib (BAY2731954) Given as Two Different Tablet Formulations or as Liquid Formulations Including the Effect of Food on the Absorption, Distribution or Excretion of the Different Formulations in Healthy Participants

NCT04771390
View directory record Official record
Conditions
Solid Tumors Harboring NTRK Fusion
Interventions
Selitrectinib (BAY2731954) Adult tablet, Selitrectinib (BAY2731954) Pediatric tablet, Selitrectinib (BAY2731954) Oral solution, Selitrectinib (BAY2731954) Oral suspension
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 55 Years
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
2
States / cities
Glendale, California • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 25, 2021 · Synced Oct 19, 2026, 4:18 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Disposition of Carbon-14-Labeled LY2886721 ([^14C]-LY2886721) Following Oral Administration in Healthy Human Participants

NCT01367262
View directory record Official record
Conditions
Healthy Volunteers
Interventions
LY2886721
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 50 Years · Male only
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Sep 13, 2019 · Synced Oct 19, 2026, 4:18 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Investigate the Absorption, Metabolism, and Excretion of [14C]-BGB-3111 in Healthy Males

NCT04163783
View directory record Official record
Conditions
Healthy Volunteers
Interventions
[14C]-BGB-3111, BGB-3111
Drug
Lead sponsor
BeiGene
Industry
Eligibility
18 Years to 65 Years
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Nov 15, 2019 · Synced Oct 19, 2026, 4:18 PM EDT
Completed Phase 1 Interventional

Oral Nifedipine to Treat Iron Overload

NCT00712738
View directory record Official record
Conditions
Thalassemia, Iron Overload, Hemochromatosis
Interventions
Nifedipine, Phlebotomy, Urinalysis, Echocardiogram, Electrocardiogram
Drug · Procedure
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 19, 2026, 4:18 PM EDT
Completed Phase 1 Interventional

Preliminary Evaluation of Uptake of [68Ga]P16-093 in Metastatic Prostate and Renal Cancer

NCT03073395
View directory record Official record
Conditions
Prostate Cancer, Renal Cancer
Interventions
[68Ga]P16-093
Drug
Lead sponsor
Five Eleven Pharma, Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 26, 2025 · Synced Oct 19, 2026, 4:18 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of [14C]-LY4065967 in Healthy Participants

NCT07039045
View directory record Official record
Conditions
Healthy
Interventions
LY4065967, [14C]-LY4065967 Oral, [14C]-LY4065967 IV
Drug · Radiation
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Sep 9, 2025 · Synced Oct 19, 2026, 4:18 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1 Study of the Absorption, Metabolism, and Excretion of [14C] PBI-200

NCT05238337
View directory record Official record
Conditions
Absorption, Metabolism and Excretion in Healthy Volunteers
Interventions
[14C]-PBI-200
Drug
Lead sponsor
Pyramid Biosciences
Industry
Eligibility
18 Years to 65 Years · Male only
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Aug 30, 2022 · Synced Oct 19, 2026, 4:18 PM EDT
Withdrawn Phase 4 Interventional

Elimination of HCV Through Linkage and In Prison Treatment of Incarcerated Populations (ECLIPSE)

NCT04235049
View directory record Official record
Conditions
HCV Infection
Interventions
Glecaprevir/pibrentasvir
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 6, 2021 · Synced Oct 19, 2026, 4:18 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of the Absorption, Distribution, Metabolism and Excretion of LY3039478 in Healthy Participants

NCT02917733
View directory record Official record
Conditions
Healthy
Interventions
LY3039478
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jul 28, 2025 · Synced Oct 19, 2026, 4:18 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Absorption, Metabolism, and Excretion Study of BIIB074

NCT02751905
View directory record Official record
Conditions
Neuropathic Pain
Interventions
BIIB074
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jun 16, 2016 · Synced Oct 19, 2026, 4:18 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Absorption, Distribution, Metabolism And Excretion Study For GSK221149A

NCT00457925
View directory record Official record
Conditions
Obstetric Labour, Premature, Premature Labor
Interventions
GSK221149A
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
30 Years to 55 Years · Female only
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2006
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Mar 19, 2012 · Synced Oct 19, 2026, 4:18 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Musculoskeletal Effects of Bicarbonate

NCT01475214
View directory record Official record
Conditions
Muscle Loss, Fractures, Osteoporosis, Age Related, Fall Injury
Interventions
potassium bicarbonate, Inactive placebo capsule
Dietary Supplement · Other
Lead sponsor
Tufts University
Other
Eligibility
60 Years and older
Enrollment
244 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2015
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 19, 2015 · Synced Oct 19, 2026, 4:18 PM EDT
Completed Phase 1 Interventional

A Study to Look at How a Single Oral Dose of 14C-OSI-906 is Absorbed, Broken Down and Eliminated in the Body

NCT01529684
View directory record Official record
Conditions
Advanced Solid Tumors, Pharmacokinetics of 14C-OSI-906
Interventions
radio-labeled OSI-906, OSI-906
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
2
States / cities
Tacoma, Washington
Source: ClinicalTrials.gov public record
Updated Nov 7, 2024 · Synced Oct 19, 2026, 4:18 PM EDT
Completed Not applicable Interventional Results available

Elimination or Prolongation of ACE Inhibitors and ARB in Coronavirus Disease 2019

NCT04338009
View directory record Official record
Conditions
COVID-19
Interventions
Discontinuation of ARB/ACEI, Continuation of ARB/ACEI
Other
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 9, 2021 · Synced Oct 19, 2026, 4:18 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

An Open-Label Phase 1 Study in Healthy Male Subjects to Investigate the Absorption, Metabolism and Excretion of [14C]-EP262 Following Single-Dose Oral Administration

NCT06645704
View directory record Official record
Conditions
Healthy Participants
Interventions
EP262
Drug
Lead sponsor
Escient Pharmaceuticals, Inc
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 24, 2025 · Synced Oct 19, 2026, 4:18 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1 Mass Balance Study of Varegacestat

NCT06845852
View directory record Official record
Conditions
Healthy Volunteer
Interventions
varegacestat
Drug
Lead sponsor
Immunome, Inc.
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Secaucus, New Jersey
Source: ClinicalTrials.gov public record
Updated Sep 26, 2025 · Synced Oct 19, 2026, 4:18 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effect of Ginkgo Biloba on Phenytoin Elimination

NCT00011063
View directory record Official record
Conditions
Healthy
Interventions
Ginkgo Biloba
Drug
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
Not listed
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2001
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 19, 2026, 4:18 PM EDT
Completed Not applicable Interventional Results available

Scheduled Awakenings for the Treatment of Nocturnal Enuresis

NCT03047720
View directory record Official record
Conditions
Nocturnal Enuresis
Interventions
Lully Sleep Guardian
Device
Lead sponsor
Indiana University
Other
Eligibility
5 Years to 17 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Nov 17, 2020 · Synced Oct 19, 2026, 4:18 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Metabolism and Excretion of BMS-986369 in Healthy Male Participants

NCT05567510
View directory record Official record
Conditions
Healthy Participants
Interventions
BMS-986369
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Feb 17, 2023 · Synced Oct 19, 2026, 4:18 PM EDT
Not yet recruiting Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Metabolism, the Routes and Extent of Elimination, and Drug Levels of [14C]Navlimetostat (BMS-986504) in Healthy Female Participants

NCT07777133
View directory record Official record
Conditions
Healthy Female Participants
Interventions
Navlimetostat, [14C]Navlimetostat
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 55 Years · Female only
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Oct 19, 2026, 4:18 PM EDT